Peptide pharmacodynamics: affinity, potency, and efficacy

Two molecules can bind the same receptor and still differ in the concentration required, the response produced, and their unwanted effects. Pharmacodynamics provides the language to describe those differences.

Affinity

Affinity expresses the tendency of a ligand to bind to its receptor under defined conditions. It is an interaction property, not a direct measure of clinical improvement. To compare it, we need to know how the assay was performed and what system was used. An isolated receptor does not replicate the full complexity of a tissue. Furthermore, the concentration available near the receptor may differ from the administered concentration. Therefore, high affinity does not guarantee a strong response in the patient. Nor does it guarantee that the compound will reach the necessary tissue. When reading an article, first identify what the researchers measured. Binding, activation, and benefit answer different questions.

Potency

Potency compares the concentration needed to achieve a predefined response. In an experimental curve, it is often summarized as an EC50. In the specified assay, a relative EC50 is the concentration producing a response halfway between that compound’s fitted lower and upper response limits. With a zero baseline, this is half its own maximum response. Different response limits mean that equal relative fractions need not represent equal absolute effects. A curve shifted toward lower concentrations suggests greater potency within that assay. However, comparison requires keeping the system and the measured response constant. We cannot directly translate cellular concentrations to clinical doses. Absorption, distribution, and elimination intervene. Nor does it mean that the most potent compound achieves a greater maximum benefit. The correct question is how much that system needs to respond, not which drug is universally better.

Pharmacological efficacy

Pharmacological efficacy refers to the ability to produce a response, including the maximum response observed in a system. One agonist may achieve a greater response than another even if it requires a higher concentration. It's important to distinguish between pharmacological efficacy and clinical efficacy. The former can be measured using a cellular signal. The latter depends on outcomes obtained in humans under a specific study design. Greater receptor activation does not, in itself, demonstrate a greater reduction in hospitalizations. It could even be accompanied by unwanted effects. When you hear that a peptide is highly effective, ask: effective for what? Then identify the model, the measured variable, and the comparator used.

Agonists and antagonists

An agonist activates the receptor and triggers a response. An antagonist reduces the action of an agonist without producing the same activation. A partial agonist achieves a lower maximum response than a full agonist in the compared system. These definitions require specifying the experimental context. The number of receptors and the efficiency of signaling can modify what we observe. Furthermore, the behavior of a molecule can differ between measured pathways. First, identify which response was compared. Then, check if there is relevant clinical evidence for the problem you are trying to solve.

Selectivity

Selectivity describes a relative preference for certain targets. It doesn't mean that a molecule has only one possible interaction. Increasing the concentration can lead to responses in other targets or tissues. It also matters which receptors each cell expresses and how it connects its signals. Therefore, a selective result in the laboratory must be interpreted within its specific conditions. In clinical practice, the relationship between the desired effect and unwanted effects is of interest. Molecular selectivity contributes to understanding this relationship, but it doesn't fully explain it. Reviewing exposure and distribution avoids attributing everything to the receptor. The reasoning must integrate where the drug arrives and what happens when it does.

Adaptation

Biological systems can adapt to persistent exposure. Some receptors change their availability or their coupling to intracellular signals. Other changes occur in broader physiological circuits. However, a reduced clinical response does not automatically demonstrate receptor desensitization. It can also reflect changes in exposure, adherence, illness, or measurement. In a patient who perceives less effect, it is helpful to reconstruct the timeline: what changed, when it changed, and how it was assessed. This review precedes any specific molecular explanation. Pharmacodynamics offers possible mechanisms, but every mechanism requires evidence. A plausible hypothesis helps in the investigation; it still does not establish the single cause of the problem.

Benefits and harms

A pharmacological response can include both desired and adverse effects. Both should be described using appropriate variables and over a sufficient period. Reducing a biomarker can be useful, but its significance depends on the disease and the desired outcome. For example, a change in glucose and a reduction in cardiovascular events represent different levels of evaluation. It is unwise to assume that one automatically demonstrates the other. In studies, review what was defined as the primary endpoint and what remained exploratory. Also consider dropout rates and tolerability. Clinical decision-making requires this combined information. A compelling curve represents part of the argument, not the entire conclusion.

What to remember

Ask which assay established potency, what maximum response was measured, and whether a patient-relevant benefit was actually evaluated. Greater experimental potency is not a reason by itself to prefer a treatment.

Continue with PEPTIDE Academy, Module 2. The complete lessons remain in the Academy; this public article introduces selected concepts.